Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2019-07-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公司高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management member (vice general manager) of the company. It includes details about the resignation, legal references, and confirms that the resignation will not impact company operations. There is no financial data, no report attached or referenced, and no mention of other filing types such as earnings, audit, or capital changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2019-07-29 Chinese
2019年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2019 年半年度报告' which translates to '2019 Semi-Annual Report'. It contains detailed financial data, including revenue, profit, cash flow, and segment analysis for the period January 1, 2019 to June 30, 2019. The content includes management discussion and analysis, business overview, financial metrics, and risk disclosures. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2019
2019-07-29 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled '2019 年半年度报告摘要' which translates to '2019 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period of 2019. It also includes discussion and analysis of business operations, industry conditions, and financial performance. The length of the document is 7915 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year, containing substantive financial data and analysis. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. H1 2019
2019-07-29 Chinese
关于2019年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a convertible bond issuance by 特一药业集团股份有限公司 for the half-year period ending June 30, 2019. It includes specifics on the amount raised, usage of funds, investment projects, cash management, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "专项报告" (special report) on the storage and use of raised funds for the 2019 half-year period. This type of document aligns with a specialized report on capital raising and fund usage rather than a general financial report or earnings release. It is not an announcement of a report publication but the report itself, given the length (7775 characters) and detailed financial data. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-07-29 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the company's investment in structured deposit products, risk warnings, risk mitigation measures, and the impact on daily operations. The document includes specific financial product details, contract information, and compliance with stock exchange rules. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a certification or voting result. It is a regulatory announcement about the use of funds and investment activities, fitting best under Regulatory Filings (RNS). The document length (6162 characters) and content support this classification rather than a report publication announcement or other categories.
2019-07-11 Chinese
关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the use of idle raised funds for cash management, including details of redeemed and ongoing cash management products, risk disclosures, and compliance with regulatory requirements. It includes specific financial figures related to cash management products but does not present comprehensive financial statements or a full financial report. The document is a formal announcement about the company's financing activities related to the use of raised funds, rather than a full annual or interim report, earnings release, or audit report. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6401 characters) and detailed financial data support this classification with high confidence.
2019-07-04 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.